Criteria | Mean | Upper 95% CL | Lower 95% CL | SD |
---|---|---|---|---|
Investigator recruitment/retention track record | 27.3 | 28.5 | 22.4 | 13.3 |
Investigator experience in previous trials | 22.7 | 23.8 | 21.6 | 12.0 |
Investigator interest | 22.42 | 23.6 | 21.3 | 13.4 |
Investigator concurrent workload | 17.2 | 18.2 | 16.2 | 9.8 |
Investigator publication track record | 10.4 | 11.3 | 9.6 | 10.9 |
Respondents (N=341) were asked to divide 100 points across the above five criteria when selecting trial sites for phase III/IV (3/4) studies: Pharma, Biotech, CROs and CTUs answered for phase III (3) studies. Medical device and all others answered for phase IV (4) studies. There was evidence of a statistically significant difference in the level of importance of the five criteria (p<0.0001). The pattern of response (not shown here) appeared to be consistent across survey respondent groupings (ie, CTU vs CRO vs industry).
CL, confidence limit; CROs, clinical research organisations; CTUs, clinical trial units.